Imaging and Targeting Coronary Artery Inflammation

1. This reference has been deleted.

2. Abbas A, Gregersen I, Holm S, Daissormont I, Bjerkeli V, Krohg-Sorensen K, Skagen KR, Dahl TB, Russell D, Almas T, Bundgaard D, Alteheld LH, Rashidi A, Dahl CP, Michelsen AE, Biessen EA, Aukrust P, Halvorsen B, and Skjelland M. Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis. Stroke 46: 793–799, 2015.

3. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, and Lambin P. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5: 4006, 2014.

4. Ait-Oufella H, Herbin O, Lahoute C, Coatrieux C, Loyer X, Joffre J, Laurans L, Ramkhelawon B, Blanc-Brude O, Karabina S, Girard CA, Payre C, Yamamoto K, Binder CJ, Murakami M, Tedgui A, Lambeau G, and Mallat Z. Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 33: 466–473, 2013.

5. Ait-Oufella H, Sage AP, Mallat Z, and Tedgui A. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ Res 114: 1640–1660, 2014.

6. Ait-Oufella H, Taleb S, Mallat Z, and Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 31: 969–979, 2011.

7. Akoumianakis I, Tarun A, and Antoniades C. Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets. Br J Pharmacol 174: 3411–3424, 2017.

8. Almer G, Frascione D, Pali-Scholl I, Vonach C, Lukschal A, Stremnitzer C, Diesner SC, Jensen-Jarolim E, Prassl R, and Mangge H. Interleukin-10: an anti-inflammatory marker to target atherosclerotic lesions via PEGylated liposomes. Mol Pharm 10: 175–186, 2013.

9. Antoniades C, Antonopoulos AS, Bendall JK, and Channon KM. Targeting redox signaling in the vascular wall: from basic science to clinical practice. Curr Pharm Des 15: 329–342, 2009.

10. Antoniades C, Antonopoulos AS, and Deanfield J. Imaging residual inflammatory cardiovascular risk. Eur Heart J 41: 748–758, 2019.

11. Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang MH, Tousoulis D, Antonopoulos AS, Demosthenous M, Marinou K, Hale A, Paschalis A, Psarros C, Triantafyllou C, Bendall J, Casadei B, Stefanadis C, and Channon KM. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 124: 335–345, 2011.

12. Antoniades C, Cunnington C, Antonopoulos A, Neville M, Margaritis M, Demosthenous M, Bendall J, Hale A, Cerrato R, Tousoulis D, Bakogiannis C, Marinou K, Toutouza M, Vlachopoulos C, Leeson P, Stefanadis C, Karpe F, and Channon KM. Induction of vascular GTP-cyclohydrolase I and endogenous tetrahydrobiopterin synthesis protect against inflammation-induced endothelial dysfunction in human atherosclerosis. Circulation 124: 1860–1870, 2011.

13. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R, Refsum H, and Channon KM. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 114: 1193–1201, 2006.

14. Antonopoulos AS, Antoniades C, Tousoulis D, Bakogiannis C, Demosthenous M, Psarros C, and Stefanadis C. Novel therapeutic strategies targeting vascular redox in human atherosclerosis. Recent Pat Cardiovasc Drug Discov 4: 76–87, 2009.

15. Antonopoulos AS, Lee R, Margaritis M, and Antoniades C. Adiponectin as a regulator of vascular redox state: therapeutic implications. Recent Pat Cardiovasc Drug Discov 6: 78–88, 2011.

16. Antonopoulos AS, Margaritis M, Coutinho P, Digby J, Patel R, Psarros C, Ntusi N, Karamitsos TD, Lee R, De Silva R, Petrou M, Sayeed R, Demosthenous M, Bakogiannis C, Wordsworth PB, Tousoulis D, Neubauer S, Channon KM, and Antoniades C. Reciprocal effects of systemic inflammation and brain natriuretic peptide on adiponectin biosynthesis in adipose tissue of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 34: 2151–2159, 2014.

17. Antonopoulos AS, Margaritis M, Coutinho P, Shirodaria C, Psarros C, Herdman L, Sanna F, De Silva R, Petrou M, Sayeed R, Krasopoulos G, Lee R, Digby J, Reilly S, Bakogiannis C, Tousoulis D, Kessler B, Casadei B, Channon KM, and Antoniades C. Adiponectin as a link between type 2 diabetes and vascular NADPH oxidase activity in the human arterial wall: the regulatory role of perivascular adipose tissue. Diabetes 64: 2207–2219, 2015.

18. Antonopoulos AS, Margaritis M, Lee R, Channon K, and Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 18: 1519–1530, 2012.

19. Antonopoulos AS, Sanna F, Sabharwal N, Thomas S, Oikonomou EK, Herdman L, Margaritis M, Shirodaria C, Kampoli AM, Akoumianakis I, Petrou M, Sayeed R, Krasopoulos G, Psarros C, Ciccone P, Brophy CM, Digby J, Kelion A, Uberoi R, Anthony S, Alexopoulos N, Tousoulis D, Achenbach S, Neubauer S, Channon KM, and Antoniades C. Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med 9: eaai2658, 2017.

20. Bäck M, Yurdagul A, Tabas I, Öörni K, and Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol 16: 389–406, 2019.

21. Badimon L and Cubedo J. Adipose tissue depots and inflammation: effects on plasticity and resident mesenchymal stem cell function. Cardiovasc Res 113: 1064–1073, 2017.

22. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, and MacWalter R. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337: a1840, 2008.

23. Ben-Chetrit E and Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 28: 48–59, 1998.

24. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, and Stein EA. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 370: 1809–1819, 2014.

25. Blumenthal HT. Cowdry's Arteriosclerosis: A Survey of the Problem. New York, NY: Thomas, 1967.

26. Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, and Braunwald E. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 132: 1224–1233, 2015.

27. Bonacina F, Moregola A, Porte R, Baragetti A, Bonavita E, Salatin A, Grigore L, Pellegatta F, Molgora M, Sironi M, Barbati E, Mantovani A, Bottazzi B, Catapano AL, Garlanda C, and Norata GD. Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity. Cardiovasc Res 115: 1861–1872, 2019.

28. Bonaventura A, Montecucco F, Dallegri F, Carbone F, Luscher TF, Camici GG, and Liberale L. Novel findings in neutrophil biology and their impact on cardiovascular disease. Cardiovasc Res 115: 1266–1285, 2019.

29. Breitzig M, Bhimineni C, Lockey R, and Kolliputi N. 4-Hydroxy-2-nonenal: a critical target in oxidative stress? Am J Physiol Cell Physiol 311: C537-C543, 2016.

30. Brown JD, Lin CY, Duan Q, Griffin G, Federation A, Paranal RM, Bair S, Newton G, Lichtman A, Kung A, Yang T, Wang H, Luscinskas FW, Croce K, Bradner JE, and Plutzky J. NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell 56: 219–231, 2014.

31. Brown MS, Ho YK, and Goldstein JL. The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem 255: 9344–9352, 1980.

32. Bulgarelli A, Leite AC Jr., Dias AA, and Maranhao RC. Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits. Cardiovasc Drugs Ther 27: 531–539, 2013.

33. Cai A, Zhou Y, and Li L. Rho-GTPase and atherosclerosis: pleiotropic effects of statins. J Am Heart Assoc 4: e002113, 2015.

34. Cai H and Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840–844, 2000.

35. Canesi F, Mateo V, Couchie D, Karabina S, Negre-Salvayre A, Rouis M, and El Hadri K. A thioredoxin-mimetic peptide exerts potent anti-inflammatory, antioxidant, and atheroprotective effects in ApoE2.Ki mice fed high fat diet. Cardiovasc Res 115: 292–301, 2019.

36. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O'Shea JJ, and Borie DC. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875–878, 2003.

37. Chiang N, Shinohara M, Dalli J, Mirakaj V, Kibi M, Choi AM, and Serhan CN. Inhaled carbon monoxide accelerates resolution of inflammation via unique proresolving mediator-heme oxygenase-1 circuits. J Immunol 190: 6378–6388, 2013.

38. Chow BJ, Small G, Yam Y, Chen L, McPherson R, Achenbach S, Al-Mallah M, Berman DS, Budoff MJ, Cademartiri F, Callister TQ, Chang HJ, Cheng VY, Chinnaiyan K, Cury R, Delago A, Dunning A, Feuchtner G, Hadamitzky M, Hausleiter J, Karlsberg RP, Kaufmann PA, Kim YJ, Leipsic J, LaBounty T, Lin F, Maffei E, Raff GL, Shaw LJ, Villines TC, and Min JK. Prognostic and therapeutic implications of statin and aspirin therapy in individuals with nonobstructive coronary artery disease: results from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter registry) registry. Arterioscler Thromb Vasc Biol 35: 981–989, 2015.

39. Cicha I, Chauvierre C, Texier I, Cabella C, Metselaar JM, Szebeni J, Dezsi L, Alexiou C, Rouzet F, Storm G, Stroes E, Bruce D, MacRitchie N, Maffia P, and Letourneur D. From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. Cardiovasc Res 114: 1714–1727, 2018.

40. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, and Mallat Z. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117: 1649–1657, 2008.

41. Cyrus T, Sung S, Zhao L, Funk CD, Tang S, and Pratico D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 106: 1282–1287, 2002.

42. Daghem M, Bing R, Fayad ZA, and Dweck MR. Noninvasive imaging to assess atherosclerotic plaque composition and disease activity: coronary and carotid applications. JACC Cardiovasc Imaging 13: 1055–1068, 2019.

43. Dietrich T, Hucko T, Schneemann C, Neumann M, Menrad A, Willuda J, Atrott K, Stibenz D, Fleck E, Graf K, and Menssen HD. Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells. Atherosclerosis 220: 329–336, 2012.

44. Diez JJ and Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148: 293–300, 2003.

45. Douglas G, Hale AB, Patel J, Chuaiphichai S, Al Haj Zen A, Rashbrook VS, Trelfa L, Crabtree MJ, McNeill E, and Channon KM. Roles for endothelial cell and macrophage Gch1 and tetrahydrobiopterin in atherosclerosis progression. Cardiovasc Res 114: 1385–1399, 2018.

46. Drummond GR, Selemidis S, Griendling KK, and Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10: 453–471, 2011.

47. Du F, Yu F, Wang Y, Hui Y, Carnevale K, Fu M, Lu H, and Fan D. MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 34: 759–767, 2014.

48. Duan L, Liu C, Hu J, Liu Y, Wang J, Chen G, Li Z, and Chen H. Epigenetic mechanisms in coronary artery disease: the current state and prospects. Trends Cardiovasc Med 28: 311–319, 2018.

49. Dufton N, Natividad J, Verdu EF, and Wallace JL. Hydrogen sulfide and resolution of acute inflammation: a comparative study utilizing a novel fluorescent probe. Sci Rep 2: 499, 2012.

50. Elnabawi YA, Dey AK, Goyal A, Groenendyk JW, Chung JH, Belur AD, Rodante J, Harrington CL, Teague HL, Baumer Y, Keel A, Playford MP, Sandfort V, Chen MY, Lockshin B, Gelfand JM, Bluemke DA, and Mehta NN. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res 115: 721–728, 2019.

51. Elnabawi YA, Oikonomou EK, Dey AK, Mancio J, Rodante JA, Aksentijevich M, Choi H, Keel A, Erb-Alvarez J, Teague HL, Joshi AA, Playford MP, Lockshin B, Choi AD, Gelfand JM, Chen MY, Bluemke DA, Shirodaria C, Antoniades C, and Mehta NN. Association of biologic therapy with coronary inflammation in patient with psoriasis as assessed by perivascular fat attenuation index. JAMA Cardiol 4: 885–891, 2019.

51a. a.Fayad ZA. Cardiovascular Inflammation Reduction Trial-Inflammation Imaging Study (CIRT)-NCT02576067. Bethesda, MD: National Library of Medicine, 2015.

52. Fiedler J, Baker AH, Dimmeler S, Heymans S, Mayr M, and Thum T. Non-coding RNAs in vascular disease—from basic science to clinical applications: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovasc Res 114: 1281–1286, 2018.

53. Fraser H, Hislop C, Christie RM, Rick HL, Reidy CA, Chouinard ML, Eacho PI, Gould KE, and Trias J. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE^−/− mice. J Cardiovasc Pharmacol 53: 60–65, 2009.

54. Fredman G, Ozcan L, Spolitu S, Hellmann J, Spite M, Backs J, and Tabas I. Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc Natl Acad Sci U S A 111: 14530–14535, 2014.

55. Galkina E and Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 27: 165–197, 2009.

56. Gast M, Rauch BH, Nakagawa S, Haghikia A, Jasina A, Haas J, Nath N, Jensen L, Stroux A, Bohm A, Friebel J, Rauch U, Skurk C, Blankenberg S, Zeller T, Prasanth KV, Meder B, Kuss A, Landmesser U, and Poller W. Immune system-mediated atherosclerosis caused by deficiency of long non-coding RNA MALAT1 in ApoE^−/− mice. Cardiovasc Res 115: 302–314, 2019.

57. Goeller M, Achenbach S, Cadet S, Kwan AC, Commandeur F, Slomka PJ, Gransar H, Albrecht MH, Tamarappoo BK, Berman DS, Marwan M, and Dey D. Pericoronary adipose tissue computed tomography attenuation and high-risk plaque characteristics in acute coronary syndrome compared with stable coronary artery disease. JAMA Cardiol 3: 858–863, 2018.

58. Goeller M, Tamarappoo BK, Kwan AC, Cadet S, Commandeur F, Razipour A, Slomka PJ, Gransar H, Chen X, Otaki Y, Friedman JD, Cao JJ, Albrecht MH, Bittner DO, Marwan M, Achenbach S, Berman DS, and Dey D. Relationship between changes in pericoronary adipose tissue attenuation and coronary plaque burden quantified from coronary computed tomography angiography. Eur Heart J Cardiovasc Imaging 20: 636–643, 2019.

59. Grebe A, Hoss F, and Latz E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ Res 122: 1722–1740, 2018.

60. Green DR, Oguin TH, and Martinez J. The clearance of dying cells: table for two. Cell Death Differ 23: 915–926, 2016.

61. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Nasir A, Setoguchi S, and Solomon DH. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 70: 576–582, 2011.

62. Griendling KK and FitzGerald GA. Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108: 1912–1916, 2003.

63. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr., Sperling L, Virani SS, and Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73: 3168–3209, 2019.

64. Guarino AJ, Tulenko TN, and Wrenn SP. Cholesterol crystal nucleation from enzymatically modified low-density lipoproteins: combined effect of sphingomyelinase and cholesterol esterase. Biochemistry 43: 1685–1693, 2004.

65. Gupta S, Sodhi S, and Mahajan V. Correlation of antioxidants with lipid peroxidation and lipid profile in patients suffering from coronary artery disease. Expert Opin Ther Targets 13: 889–894, 2009.

66. Hajmirza A, Emadali A, Gauthier A, Casasnovas O, Gressin R, and Callanan MB. BET family protein BRD4: An emerging actor in NFkappaB signaling in inflammation and cancer. Biomedicines 6: 16, 2018.

67. Hakimzadeh N, Pinas VA, Molenaar G, de Waard V, Lutgens E, van Eck-Smit BLF, de Bruin K, Piek JJ, Eersels JLH, Booij J, Verberne HJ, and Windhorst AD. Novel molecular imaging ligands targeting matrix metalloproteinases 2 and 9 for imaging of unstable atherosclerotic plaques. PLoS One 12: e0187767, 2017.

68. Han X and Boisvert WA. Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage function. Thromb Haemost 113: 505–512, 2015.

69. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685–1695, 2005.

70. Hedgire S, Baliyan V, Zucker EJ, Bittner DO, Staziaki PV, Takx RAP, Scholtz JE, Meyersohn N, Hoffmann U, and Ghoshhajra B. Perivascular epicardial fat stranding at coronary CT angiography: a marker of acute plaque rupture and spontaneous coronary artery dissection. Radiology 287: 808–815, 2018.

71. Hennessy T, Soh L, Bowman M, Kurup R, Schultz C, Patel S, and Hillis GS. The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J 215: 62–69, 2019.

72. Herova M, Schmid M, Gemperle C, Loretz C, and Hersberger M. Low dose aspirin is associated with plasma chemerin levels and may reduce adipose tissue inflammation. Atherosclerosis 235: 256–262, 2014.

73. Houde M and Van Eck M. Escaping the atherogenic trap: preventing LDL fusion and binding in the intima. Atherosclerosis 275: 376–378, 2018.

74. Huang CX, Zhang YL, Wang JF, Jiang JY, and Bao JL. MCP-1 impacts RCT by repressing ABCA1, ABCG1, and SR-BI through PI3K/Akt posttranslational regulation in HepG2 cells. J Lipid Res 54: 1231–1240, 2013.

75. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, and Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100: 793–798, 1999.

76. Immordino ML, Dosio F, and Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1: 297–315, 2006.

77. Jenkins W, Vickers A, Vesey AT, Dweck M, and Newby DE. 18F-fluciclatide positron emission tomography is a novel marker of AVB3 expression in aortic atherosclerosis. Atherosclerosis 241: e162, 2015.

78. Jenkins WS, Vesey AT, Vickers A, Neale A, Moles C, Connell M, Joshi NV, Lucatelli C, Fletcher AM, Spratt JC, Mirsadraee S, van Beek EJR, Rudd JHF, Newby DE, and Dweck MR. In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis. Heart 105: 1868, 2019.

79. Jonasson L and Hansson G. [Inflammation and atherosclerosis - last piece of the puzzle has fallen into place]. Lakartidningen 114: EU6R, 2017 (Article in Swedish).

80. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, and Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375: 132–140, 2010.

81. Kaufmann BA, Carr CL, Belcik JT, Xie A, Yue Q, Chadderdon S, Caplan ES, Khangura J, Bullens S, Bunting S, and Lindner JR. Molecular imaging of the initial inflammatory response in atherosclerosis. Arterioscler Thromb Vasc Biol 30: 54–59, 2010.

82. Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, and Lindner JR. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation 116: 276–284, 2007.

83. Ketelhuth DF and Hansson GK. Adaptive response of T and B cells in atherosclerosis. Circ Res 118: 668–678, 2016.

84. Ketelhuth DFJ, Lutgens E, Back M, Binder CJ, Van den Bossche J, Daniel C, Dumitriu IE, Hoefer I, Libby P, O'Neill L, Weber C, and Evans PC. Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. Cardiovasc Res 115: 1385–1392, 2019.

85. Kharbanda RK, Walton B, Allen M, Klein N, Hingorani AD, MacAllister RJ, and Vallance P. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 105: 2600–2604, 2002.

86. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, and Group ESD. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 41: 407–477, 2020.

87. Kolossvary M, Karady J, Szilveszter B, Kitslaar P, Hoffmann U, Merkely B, and Maurovich-Horvat P. Radiomic features are superior to conventional quantitative computed tomographic metrics to identify coronary plaques with napkin-ring sign. Circ Cardiovasc Imaging 10: pii:e006843, 2017.

88. Kolossvary M, Kellermayer M, Merkely B, and Maurovich-Horvat P. Cardiac computed tomography radiomics: a comprehensive review on radiomic techniques. J Thorac Imaging 33: 26–34, 2018.

89. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004–1010, 2000.

90. Kwiecinski J, Dey D, Cadet S, Lee SE, Otaki Y, Huynh PT, Doris MK, Eisenberg E, Yun M, Jansen MA, Williams MC, Tamarappoo BK, Friedman JD, Dweck MR, Newby DE, Chang HJ, Slomka PJ, and Berman DS. Peri-coronary adipose tissue density is associated with (18)F-sodium fluoride coronary uptake in stable patients with high-risk plaques. JACC Cardiovasc Imaging 12: 2000–2010, 2019.

91. Lehti S, Nguyen SD, Belevich I, Vihinen H, Heikkila HM, Soliymani R, Kakela R, Saksi J, Jauhiainen M, Grabowski GA, Kummu O, Horkko S, Baumann M, Lindsberg PJ, Jokitalo E, Kovanen PT, and Oorni K. extracellular lipids accumulate in human carotid arteries as distinct three-dimensional structures and have proinflammatory properties. Am J Pathol 188: 525–538, 2018.

92. Li X, Ballantyne LL, Che X, Mewburn JD, Kang JX, Barkley RM, Murphy RC, Yu Y, and Funk CD. Endogenously generated omega-3 fatty acids attenuate vascular inflammation and neointimal hyperplasia by interaction with free fatty acid receptor 4 in mice. J Am Heart Assoc 4: e001856, 2015.

93. Liao JK and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89–118, 2005.

94. Libby P, Pasterkamp G, Crea F, and Jang I-K. Reassessing the mechanisms of acute coronary syndromes. 124: 150–160, 2019.

95. Libby P, Ridker PM, and Maseri A. Inflammation and atherosclerosis. Circulation 105: 1135–1143, 2002.

96. Liu H, Jiang D, Zhang S, and Ou B. Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. Cardiovasc Drugs Ther 24: 17–24, 2010.

97. Lobstein JGCFM. Traites d'Anatomie Pathologique. Paris, France: Chez F.G. Levrault, 1833.

98. Luehmann HP, Detering L, Fors BP, Pressly ED, Woodard PK, Randolph GJ, Gropler RJ, Hawker CJ, and Liu Y. PET/CT imaging of chemokine receptors in inflammatory atherosclerosis using targeted nanoparticles. J Nucl Med 57: 1124–1129, 2016.

99. MacAskill MG, Newby DE, and Tavares AAS. Frontiers in positron emission tomography imaging of the vulnerable atherosclerotic plaque. Cardiovasc Res 115: 1952–1962, 2019.

100. Madonna R, Massaro M, Scoditti E, Pescetelli I, and De Caterina R. The epicardial adipose tissue and the coronary arteries: dangerous liaisons. Cardiovasc Res 115: 1013–1025, 2019.

101. Mancio J, Azevedo D, Saraiva F, Azevedo AI, Pires-Morais G, Leite-Moreira A, Falcao-Pires I, Lunet N, and Bettencourt N. Epicardial adipose tissue volume assessed by computed tomography and coronary artery disease: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging 19: 490–497, 2018.

102. Mancio J, Oikonomou EK, and Antoniades C. Perivascular adipose tissue and coronary atherosclerosis. Heart 104: 1654–1662, 2018.

103. Margaritis M, Antonopoulos AS, Digby J, Lee R, Reilly S, Coutinho P, Shirodaria C, Sayeed R, Petrou M, De Silva R, Jalilzadeh S, Demosthenous M, Bakogiannis C, Tousoulis D, Stefanadis C, Choudhury RP, Casadei B, Channon KM, and Antoniades C. Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation 127: 2209–2221, 2013.

104. Margaritis M, Channon KM, and Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal 20: 1198–1215, 2014.

105. McKee S. Novartis pulls EU filing for canakinumab. PharmaTimes. London, United Kingdom, 2018.

106. McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, Ryan J, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Radziszewska B, Grimm R, and Murray AM. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 379: 1519–1528, 2018.

107. Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, and Mozaffarian D. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108: 1362–1370, 2011.

108. Miller J. FDA Snubs Novartis Bid to Repurpose Inflammation Drug for Heart Attacks. Zurich, Switzerland: Reuters, 2018.

109. Mohler ER, 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, and Zalewski A. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 51: 1632–1641, 2008.

110. Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, Newson J, Bellingan G, and Gilroy DW. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 183: 2089–2096, 2009.

111. Nahrendorf M, Keliher E, Panizzi P, Zhang H, Hembrador S, Figueiredo JL, Aikawa E, Kelly K, Libby P, and Weissleder R. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging 2: 1213–1222, 2009.

112. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, Komatsu R, Ikura Y, Ogami M, Shimada Y, Ehara S, Yoshiyama M, Takeuchi K, Yoshikawa J, and Becker AE. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106: 2894–2900, 2002.

113. Nash M, McGrath JP, Cartland SP, Patel S, and Kavurma MM. Tumour necrosis factor superfamily members in ischaemic vascular diseases. Cardiovasc Res 115: 713–720, 2019.

114. Nicholls SJ, Ray KK, Johansson JO, Gordon A, Sweeney M, Halliday C, Kulikowski E, Wong N, Kim SW, and Schwartz GG. Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease. Am J Cardiovasc Drugs 18: 109–115, 2018.

115. Nidorf SM, Eikelboom JW, Budgeon CA, and Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61: 404–410, 2013.

116. O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP, and Steen DL. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 312: 1006–1015, 2014.

117. Ohyama K, Matsumoto Y, Takanami K, Ota H, Nishimiya K, Sugisawa J, Tsuchiya S, Amamizu H, Uzuka H, Suda A, Shindo T, Kikuchi Y, Hao K, Tsuburaya R, Takahashi J, Miyata S, Sakata Y, Takase K, and Shimokawa H. Coronary adventitial and perivascular adipose tissue inflammation in patients with vasospastic angina. J Am Coll Cardiol 71: 414–425, 2018.

118. Oikonomou EK and Antoniades C. The role of adipose tissue in cardiovascular health and disease. Nat Rev Cardiol 16: 83–99, 2018.

119. Oikonomou EK, Marwan M, Desai MY, Mancio J, Alashi A, Hutt Centeno E, Thomas S, Herdman L, Kotanidis CP, Thomas KE, Griffin BP, Flamm SD, Antonopoulos AS, Shirodaria C, Sabharwal N, Deanfield J, Neubauer S, Hopewell JC, Channon KM, Achenbach S, and Antoniades C. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet 392: 929–939, 2018.

120. Oikonomou EK, Williams MC, Kotanidis CP, Desai MY, Marwan M, Antonopoulos AS, Thomas KE, Thomas S, Akoumianakis I, Fan LM, Kesavan S, Herdman L, Alashi A, Centeno EH, Lyasheva M, Griffin BP, Flamm SD, Shirodaria C, Sabharwal N, Kelion A, Dweck MR, Van Beek EJR, Deanfield J, Hopewell JC, Neubauer S, Channon KM, Achenbach S, Newby DE, and Antoniades C. A novel machine learning-derived radiotranscriptomic signature of perivascular fat improves cardiac risk prediction using coronary CT angiography. Eur Heart J 40: 3529–3543, 2019.

121. Oikonomou Evangelos K, West Henry W, and Antoniades C. Cardiac computed tomography. Arterioscler Thromb Vasc Biol 39: 2207–2219, 2019.

122. Oorni K, Rajamaki K, Nguyen SD, Lahdesmaki K, Plihtari R, Lee-Rueckert M, and Kovanen PT. Acidification of the intimal fluid: the perfect storm for atherogenesis. J Lipid Res 56: 203–214, 2015.

123. Ouchi N, Parker JL, Lugus JJ, and Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11: 85–97, 2011.

124. Pastrana JL, Sha X, Virtue A, Mai J, Cueto R, Lee IA, Wang H, and Yang XF. Regulatory T cells and atherosclerosis. J Clin Exp Cardiol 2012: 2, 2012.

125. Patel MN, Carroll RG, Galvan-Pena S, Mills EL, Olden R, Triantafilou M, Wolf AI, Bryant CE, Triantafilou K, and Masters SL. inflammasome priming in sterile inflammatory disease. Trends Mol Med 23: 165–180, 2017.

126. Paulson KE, Zhu SN, Chen M, Nurmohamed S, Jongstra-Bilen J, and Cybulsky MI. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ Res 106: 383–390, 2010.

127. Pentikainen MO, Oorni K, Ala-Korpela M, and Kovanen PT. Modified LDL-trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med 247: 359–370, 2000.

128. Perneby C, Wallen NH, Rooney C, Fitzgerald D, and Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 95: 652–658, 2006.

129. Perretti M, Leroy X, Bland EJ, and Montero-Melendez T. Resolution pharmacology: opportunities for therapeutic innovation in inflammation. Trends Pharmacol Sci 36: 737–755, 2015.

130. Pirkmajer S, Kulkarni SS, Tom RZ, Ross FA, Hawley SA, Hardie DG, Zierath JR, and Chibalin AV. Methotrexate promotes glucose uptake and lipid oxidation in skeletal muscle via AMPK activation. Diabetes 64: 360–369, 2015.

131. Pober JS and Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 7: 803–815, 2007.

132. Punjabi M, Xu L, Ochoa-Espinosa A, Kosareva A, Wolff T, Murtaja A, Broisat A, Devoogdt N, and Kaufmann BA. Ultrasound molecular imaging of atherosclerosis with nanobodies. Arterioscler Thromb Vasc Biol 39: 2520–2530, 2019.

133. Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Maatta A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Yla-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, and Witztum JL. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558: 301–306, 2018.

134. Radmark O and Samuelsson B. Regulation of 5-lipoxygenase enzyme activity. Biochem Biophys Res Commun 338: 102–110, 2005.

135. Raggi P, Senior P, Shahbaz S, Kaul P, Hung R, Coulden R, Yeung R, and Abele J. (18)F-sodium fluoride imaging of coronary atherosclerosis in ambulatory patients with diabetes mellitus. Arterioscler Thromb Vasc Biol 39: 276–284, 2019.

136. Rajamaki K, Lappalainen J, Oorni K, Valimaki E, Matikainen S, Kovanen PT, and Eklund KK. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 5: e11765, 2010.

137. Ramji DP and Davies TS. Cytokines in atherosclerosis: key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev 26: 673–685, 2015.

138. Ray KK, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Schwartz GG, and BETonMACE Investigators and Committees. Effect of apabetalone added to standard therapy on major adverse cardiovascular events in patients with recent acute coronary syndrome and type 2 diabetes: a randomized clinical trial. JAMA 323: 1565–1573, 2020.

139. Razavian M, Tavakoli S, Zhang J, Nie L, Dobrucki LW, Sinusas AJ, Azure M, Robinson S, and Sadeghi MM. Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation. J Nucl Med 52: 1795–1802, 2011.

140. Rezaie-Majd A, Prager GW, Bucek RA, Schernthaner GH, Maca T, Kress HG, Valent P, Binder BR, Minar E, and Baghestanian M. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 23: 397–403, 2003.

141. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, and Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973–979, 1997.

142. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, and Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207, 2008.

143. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, and Glynn RJ. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377: 1119–1131, 2017.

144. Ridker PM, MacFadyen J, Libby P, and Glynn RJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Am J Cardiol 106: 204–209, 2010.

145. Robinson JG, Smith B, Maheshwari N, and Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46: 1855–1862, 2005.

146. Rosenson RS. Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. Curr Opin Lipidol 21: 473–480, 2010.

147. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 340: 115–126, 1999.

148. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, and Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74: 480–489, 2015.

149. Ruuth M, Nguyen SD, Vihervaara T, Hilvo M, Laajala TD, Kondadi PK, Gistera A, Lahteenmaki H, Kittila T, Huusko J, Uusitupa M, Schwab U, Savolainen MJ, Sinisalo J, Lokki ML, Nieminen MS, Jula A, Perola M, Yla-Herttula S, Rudel L, Oorni A, Baumann M, Baruch A, Laaksonen R, Ketelhuth DFJ, Aittokallio T, Jauhiainen M, Kakela R, Boren J, Williams KJ, Kovanen PT, and Oorni K. Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. Eur Heart J 39: 2562–2573, 2018.

150. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, and Menter A. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306: 864–871, 2011.

151. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM, 3rd, Trocha SD, Huang PL, Smith MB, Lefer AM, and Lefer DJ. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 103: 2598–2603, 2001.

152. Schurmann C, Dienst FL, Palfi K, Vasconez AE, Oo JA, Wang S, Buchmann GK, Offermanns S, van de Sluis B, Leisegang MS, Gunther S, Humbert PO, Lee E, Zhu J, Weigert A, Mathoor P, Wittig I, Kruse C, and Brandes RP. The polarity protein Scrib limits atherosclerosis development in mice. Cardiovasc Res 115: 1963–1974, 2019.

153. Seidah NG, Prat A, Pirillo A, Catapano AL, and Norata GD. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. Cardiovasc Res 115: 510–518, 2019.

154. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510: 92–101, 2014.

155. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, and Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J 21: 325–332, 2007.

156. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, and Zalewski A. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118: 1172–1182, 2008.

157. Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, and Sattar N. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J Am Coll Cardiol 62: 717–729, 2013.

158. Shashkin P, Dragulev B, and Ley K. Macrophage differentiation to foam cells. Curr Pharm Des 11: 3061–3072, 2005.

159. Siti HN, Kamisah Y, and Kamsiah J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul Pharmacol 71: 40–56, 2015.

160. Soedamah-Muthu SS, Livingstone SJ, Charlton-Menys V, Betteridge DJ, Hitman GA, Neil HA, Bao W, DeMicco DA, Preston GM, Fuller JH, Stehouwer CD, Schalkwijk CG, Durrington PN, and Colhoun HM. Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. Diabetologia 58: 1494–1502, 2015.

161. Soehnlein O, Drechsler M, Doring Y, Lievens D, Hartwig H, Kemmerich K, Ortega-Gomez A, Mandl M, Vijayan S, Projahn D, Garlichs CD, Koenen RR, Hristov M, Lutgens E, Zernecke A, and Weber C. Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol Med 5: 471–481, 2013.

162. Steffens S, Burger F, Pelli G, Dean Y, Elson G, Kosco-Vilbois M, Chatenoud L, and Mach F. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation 114: 1977–1984, 2006.

163. Tabas I and Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339: 166–172, 2013.

164. Tajbakhsh A, Rezaee M, Kovanen PT, and Sahebkar A. Efferocytosis in atherosclerotic lesions: malfunctioning regulatory pathways and control mechanisms. Pharmacol Ther 188: 12–25, 2018.

165. Tarkin JM, Calcagno C, Dweck MR, Evans NR, Chowdhury MM, Gopalan D, Newby DE, Fayad ZA, Bennett MR, and Rudd JHF. 68Ga-DOTATATE PET identifies residual myocardial inflammation and bone marrow activation after myocardial infarction. J Am Coll Cardiol 73: 2489–2491, 2019.

166. Tarkin JM, Joshi FR, Evans NR, Chowdhury MM, Figg NL, Shah AV, Starks LT, Martin-Garrido A, Manavaki R, Yu E, Kuc RE, Grassi L, Kreuzhuber R, Kostadima MA, Frontini M, Kirkpatrick PJ, Coughlin PA, Gopalan D, Fryer TD, Buscombe JR, Groves AM, Ouwehand WH, Bennett MR, Warburton EA, Davenport AP, and Rudd JH. Detection of atherosclerotic inflammation by (68)Ga-DOTATATE PET compared to [(18)F]FDG PET imaging. J Am Coll Cardiol 69: 1774–1791, 2017.

167. Tarkin JM, Mason JC, and Fayad ZA. Imaging at the inter-face of inflammation and angiogenesis by ¹⁸F-fluciclatide PET. Heart 105: 1845, 2019.

168. Tedgui A, and Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86: 515–581, 2006.

169. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, and Cua DJ. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 21: 719–729, 2015.

170. Teupser D, Pavlides S, Tan M, Gutierrez-Ramos JC, Kolbeck R, and Breslow JL. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci U S A 101: 17795–17800, 2004.

171. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, and Danesh J. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375: 1536–1544, 2010.

172. Thorp E, Subramanian M, and Tabas I. The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis. Eur J Immunol 41: 2515–2518, 2011.

173. Tian Y, Sommerville LJ, Cuneo A, Kelemen SE, and Autieri MV. Expression and suppressive effects of interleukin-19 on vascular smooth muscle cell pathophysiology and development of intimal hyperplasia. Am J Pathol 173: 901–909, 2008.

174. Toth L, Muszbek L, and Komaromi I. Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations. J Mol Graph Model 40: 99–109, 2013.

175. Tousoulis D, Oikonomou E, Economou EK, Crea F, and Kaski JC. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J 37: 1723–1732, 2016.

176. Tunon J, Badimon L, Bochaton-Piallat ML, Cariou B, Daemen MJ, Egido J, Evans PC, Hoefer IE, Ketelhuth DFJ, Lutgens E, Matter CM, Monaco C, Steffens S, Stroes E, Vindis C, Weber C, and Back M. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovasc Res 115: 10–19, 2019.

177. Turner MD, Nedjai B, Hurst T, and Pennington DJ. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta 1843: 2563–2582, 2014.

178. Tzellos T, Kyrgidis A, and Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 27: 622–627, 2013.

179. van Duijn J, Kritikou E, Benne N, van der Heijden T, van Puijvelde GH, Kroner MJ, Schaftenaar FH, Foks AC, Wezel A, Smeets H, Yagita H, Bot I, Jiskoot W, Kuiper J, and Slutter B. CD8+ T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4+ T-cell responses. Cardiovasc Res 115: 729–738, 2019.

180. van Koeverden ID, de Bakker M, Haitjema S, van der Laan SW, de Vries JPM, Hoefer IE, de Borst GJ, Pasterkamp G, and den Ruijter HM. Testosterone to oestradiol ratio reflects systemic and plaque inflammation and predicts future cardiovascular events in men with severe atherosclerosis. Cardiovasc Res 115: 453–462, 2019.

181. van Kuijk K, Kuppe C, Betsholtz C, Vanlandewijck M, Kramann R, and Sluimer JC. Heterogeneity and plasticity in healthy and atherosclerotic vasculature explored by single-cell sequencing. Cardiovasc Res 115: 1705–1715, 2019.

182. Wallace JL, Ianaro A, Flannigan KL, and Cirino G. Gaseous mediators in resolution of inflammation. Semin Immunol 27: 227–233, 2015.

183. Wang X, and Peter K. Molecular imaging of atherothrombotic diseases. Arterioscler Thromb Vasc Biol 37: 1029–1040, 2017.

184. Weber C, and Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17: 1410–1422, 2011.

185. Welsh P, Grassia G, Botha S, Sattar N, and Maffia P. Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? Br J Pharmacol 174: 3898–3913, 2017.

186. Werz O, Klemm J, Samuelsson B, and Radmark O. 5-Lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc Natl Acad Sci U S A 97: 5261–5266, 2000.

187. Westerterp M, Gautier EL, Ganda A, Molusky MM, Wang W, Fotakis P, Wang N, Randolph GJ, D'Agati VD, Yvan-Charvet L, and Tall AR. Cholesterol accumulation in dendritic cells links the inflammasome to acquired immunity. cell Metab 25: 1294–1304.e6, 2017.

188. White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, Lopez-Sendon J, Manolis AJ, Mohler ER, 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, and Wallentin L. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 370: 1702–1711, 2014.

189. Wilensky RL, Shi Y, Mohler ER, 3rd, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, and Macphee CH. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 14: 1059–1066, 2008.

190. World Health Organization. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2016. Geneva, Switzerland: World Health Organisation, 2018.

191. Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, Kolodny G, and Laham R. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 50: 563–568, 2009.

192. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, and Achong MK. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101: 311–320, 1998.

193. Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, Sakai N, and Ogihara T. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element ‘decoy’ of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther 8: 1635–1642, 2001.

194. Zhao L, Cuff CA, Moss E, Wille U, Cyrus T, Klein EA, Pratico D, Rader DJ, Hunter CA, Pure E, and Funk CD. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem 277: 35350–35356, 2002.

195. Ziegler L, Gajulapuri A, Frumento P, Bonomi A, Wallen H, de Faire U, Rose-John S, and Gigante B. Interleukin 6 trans-signalling and risk of future cardiovascular events. Cardiovasc Res 115: 213–221, 2019.